deaths (OS)progression or deaths (PFS)RFS/DFS

mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-25% certainty unassessablestatistically conclusive-32%-